Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase II study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase II clinical study for treating patients with acute myocardial infarction; and, which is in Phase I/II clinical study for treating patients with acute respiratory distress syndrome, as well as that has completed Phase I clinical study for patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical need. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke in Japan; RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; the University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATHX
Previous Symbol
CUSIPN/A
Phone216-431-9900
Debt
Debt-to-Equity RatioN/A
Current Ratio4.56
Quick Ratio4.56
Price-To-Earnings
Trailing P/E Ratio-6.62
Forward P/E Ratio-10.11
P/E GrowthN/A
Sales & Book Value
Annual Sales$3.71 million
Price / Sales73.36
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.20 per share
Price / Book9.60
Profitability
EPS (Most Recent Fiscal Year)($0.29)
Net Income$-32,240,000.00
Net Margins-108.83%
Return on Equity-58.74%
Return on Assets-44.56%
Miscellaneous
Employees66
Outstanding Shares141,750,000
Market Cap$282.07 million
OptionableOptionable
Athersys (NASDAQ:ATHX) Frequently Asked Questions
What is Athersys' stock symbol?
Athersys trades on the NASDAQ under the ticker symbol "ATHX."
How were Athersys' earnings last quarter?
Athersys, Inc. (NASDAQ:ATHX) posted its quarterly earnings data on Tuesday, November, 6th. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.08) by $0.01. The biopharmaceutical company earned $2.32 million during the quarter, compared to analyst estimates of $1.80 million. Athersys had a negative return on equity of 58.74% and a negative net margin of 108.83%. View Athersys' Earnings History.
When is Athersys' next earnings date?
What price target have analysts set for ATHX?
1 analysts have issued twelve-month price objectives for Athersys' shares. Their predictions range from $6.00 to $6.00. On average, they expect Athersys' stock price to reach $6.00 in the next year. This suggests a possible upside of 212.5% from the stock's current price. View Analyst Price Targets for Athersys.
What is the consensus analysts' recommendation for Athersys?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Athersys.
What are Wall Street analysts saying about Athersys stock?
Here are some recent quotes from research analysts about Athersys stock:
- 1. According to Zacks Investment Research, "Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is also developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). Athersys is developing MultiStem(r), its patented, adult-derived ``off the shelf'' stem cell product platform, for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications. " (11/12/2018)
- 2. Maxim Group analysts commented, "Athersys reported 2Q18 with $19.4M in revenue, which includes $18.5M related to the expanded partnership with Helios (6927JP – NR). With operating expenses just over $12M, the company ended the period with net income of $6.9M, as well as $53.4M in cash on the balance sheet." (8/8/2018)
Has Athersys been receiving favorable news coverage?
News stories about ATHX stock have trended very negative recently, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Athersys earned a news sentiment score of -3.8 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future.
Who are some of Athersys' key competitors?
Some companies that are related to Athersys include Uniqure (QURE), Apellis Pharmaceuticals (APLS), Retrophin (RTRX), Rhythm Pharmaceuticals (RYTM), TherapeuticsMD (TXMD), Amphastar Pharmaceuticals (AMPH), Deciphera Pharmaceuticals (DCPH), Homology Medicines (FIXX), Puma Biotechnology (PBYI), Athenex (ATNX), Crinetics Pharmaceuticals (CRNX), ImmunoGen (IMGN), Intra-Cellular Therapies (ITCI), Dicerna Pharmaceuticals (DRNA) and AC Immune (ACIU).
Who are Athersys' key executives?
Athersys' management team includes the folowing people:
- Dr. Gil Van Bokkelen, Co-Founder, Chairman & CEO (Age 57)
- Mr. William B. J. Lehmann Jr., Pres, COO & Sec. (Age 52)
- Dr. John J. Harrington, Co-Founder, Chief Scientific Officer, Exec. VP & Director (Age 51)
- Ms. Laura K. Campbell, Sr. VP of Fin. (Age 54)
- Dr. Manal Morsy M.D., PH.D., Sr. VP & Head of Global Regulatory Affairs
Who are Athersys' major shareholders?
Athersys' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.88%), Vanguard Group Inc (4.03%), Vanguard Group Inc. (4.03%), TIAA CREF Investment Management LLC (0.33%), Alps Advisors Inc. (0.18%) and Renaissance Technologies LLC (0.17%). Company insiders that own Athersys stock include Ismail Kola, John J Harrington, Laura K Campbell and William Lehmann Jr. View Institutional Ownership Trends for Athersys.
Which major investors are selling Athersys stock?
ATHX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have sold Athersys company stock in the last year include John J Harrington, Laura K Campbell and William Lehmann Jr. View Insider Buying and Selling for Athersys.
Which major investors are buying Athersys stock?
ATHX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., TIAA CREF Investment Management LLC, Vanguard Group Inc, Vanguard Group Inc., Alps Advisors Inc. and Marshall Wace LLP. Company insiders that have bought Athersys stock in the last two years include Ismail Kola and Laura K Campbell. View Insider Buying and Selling for Athersys.
How do I buy shares of Athersys?
Shares of ATHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Athersys' stock price today?
One share of ATHX stock can currently be purchased for approximately $1.92.
How big of a company is Athersys?
Athersys has a market capitalization of $282.07 million and generates $3.71 million in revenue each year. The biopharmaceutical company earns $-32,240,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. Athersys employs 66 workers across the globe.
What is Athersys' official website?
How can I contact Athersys?
Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company can be reached via phone at 216-431-9900 or via email at [email protected]
MarketBeat Community Rating for Athersys (NASDAQ ATHX)
MarketBeat's community ratings are surveys of what our community members think about Athersys and other stocks. Vote "Outperform" if you believe ATHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATHX will underperform the S&P 500 over the long term. You may vote once every thirty days.
